The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Future mechanistic strategies for tackling fibrosis–an unmet need in liver disease
Open accessAbstract
Standardised mortality rates for liver disease in the UK have increased 400% since 1970. However, evidence from a large number of animal models and clinical trials indicates that liver fibrosis and even cirrhosis are potentially reversible if the underlying cause can be successfully removed. Nevertheless, in a significant number of patients cure of the underlying disease may not result in fibrosis regression, and no antifibrotic drug has been licenced by the United States Food and Drug Administration or the European Medicines Agency. Dissection of the mechanistic pathways and regulatory factors that characterise matrix remodelling and architectural repair during fibrosis regression are revealing novel therapeutic approaches to induce liver repair. Points of attack in the fibrotic cascade include promoting the loss of hepatic myofibroblasts, inhibiting profibrogenic properties of myofibroblasts, stimulating degradation of accumulated liver scar tissue, targeting the immune response, and cell-based therapies. Therapeutic candidates are now being evaluated in early-phase human trials but translation into the clinic will require careful patient selection and stratification, and the definition and validation of clinically meaningful endpoints.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hepatocyte injury, apoptosis and necrosis promote a sterile inflammatory response. This includes activation of KCs to clear necrotic debris, recruitment of lymphocytes and bone-marrow-derived monocytes, extracellular matrix (ECM) remodelling, myofibroblast activation, angiogenesis, and hepatocyte regeneration and differentiation to replace lost hepatocytes.11,31,32”
From Understanding the cellular interactome of non-alcoholic fatty liver disease (2022) · cites this paper as [32]
Citations
Cites
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair
Duffield, J. S., Forbes, S. J., Constandinou, C. M., Clay, S., Partolina, M., Vuthoori, S., Wu, S., Lang, R., & Iredale, J. P. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200522675 · Cited by 1,649
Liver fibrosis and repair: Immune regulation of wound healing in a solid organ
Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A. (2014) · Nature Reviews Immunology · doi:10.1038/nri3623 · Cited by 1,310
Self-citationRamachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001
Self-citationBarry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870
Henderson, N. C., Arnold, T. D., Katamura, Y., Giacomini, M. M., Rodriguez, J. D., McCarty, J. H., Pellicoro, A., Raschperger, E., Betsholtz, C., Ruminski, P. G., et al. (2013) · Nature Medicine · doi:10.1038/nm.3282 · Cited by 866
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201840109 · Cited by 805
Research works printed but not linked: 1
- Iredale, 1998, Mechanisms of spontaneous resolution of rat liver fibrosis, Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest, 102, 535
Cited by
Determinants of Fibrosis Progression and Regression in NASH
Schuppan, D., Surabattula, R., & Wang, X. Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.012 · Cited by 479
“, HSC/MF, addressing the immune system and especially macrophages, is an attractive strategy to induce regression of once established fibrosis (55,63,65,51,53,56,68,115-117).”
BackgroundInfluentialThe peritoneum: healing, immunity, and diseases
Capobianco, A., Cottone, L., Monno, A., Manfredi, A. A., & Rovere‐Querini, P. (2017) · The Journal of Pathology · doi:10.1002/path.4942 · Cited by 162
“It is known that hepatic fibrosis and even cirrhosis are potentially reversible if the underlying cause is removed [42].”
BackgroundUnderstanding the cellular interactome of non-alcoholic fatty liver disease
Wallace, S. J., Tacke, F., Schwabe, R. F., & Henderson, N. C. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100524 · Cited by 116
“myofibroblast activation, angiogenesis, and hepatocyte regeneration and differentiation to replace lost hepatocytes.(11,31,32) In NASH, hepatocytes undergo apoptosis, necroptosis or pyroptosis”
BackgroundThe innate immune receptor TREM-1 promotes liver injury and fibrosis
Nguyen-Lefebvre, A. T., Ajith, A., Portik-Dobos, V., Horuzsko, D. D., Arbab, A. S., Dzutsev, A., Sadek, R., Trinchieri, G., & Horuzsko, A. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98156 · Cited by 104
Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment
Talal, A. H., Venuto, C. S., & Younis, I. R. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.336 · Cited by 45
Metadata
- Authors
- Fallowfield, J. A.
- Affiliations
- Centre for Inflammation Research (GB)
- Corresponding author
- Fallowfield, Jonathan A
- Venue
- Clinical Medicine
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 15
- Issue
- 6
- Pages
- s83-s87
- ISSN
- 1470-2118 (ISSN-L)
- OpenAlex
- W2183791618
- Cited by
- 15
- References
- 31
- Citations by year
- 2025: 2 · 2024: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 4
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3055 d)
- Locations
- Clinical Medicine (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Academy of Medical Sciences (AMS-CSF3-Fallowfield)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- liver fibrosis, antifibrotic therapy, fibrosis regression, myofibroblasts, extracellular matrix remodeling, liver repair, liver cirrhosis, cell therapy, fibrosis biomarkers, clinical trial endpoints, patient selection
- MeSH terms
- Humans, Liver Cirrhosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Future mechanistic strategies for tackling fibrosis–an unmet need in liver disease. https://app.cochat.ai/papers/10.7861/clinmedicine.15-6-s83
- The paper
- Fallowfield, J. A. (2015). Future mechanistic strategies for tackling fibrosis–an unmet need in liver disease. Clinical Medicine. https://doi.org/10.7861/clinmedicine.15-6-s83
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.